From major weight loss and improved mood to serious side effects, people with bipolar disorder share what happened when they ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

The global populating is aging, and approximately 29% of people with diabetes worldwide are aged 65 years and older, ...

Recently, it has been popularly labeled "nature’s Ozempic," referencing its claimed similarities to the pharmaceutical agent Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor ...

“Last time I did go to the doctor, since my A1C was ... pressure reduction, mental health, BMI, and fat tissue decrease. “The most common reason to take a patient off a GLP-1 medication ...

Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP ... reduction versus 5% from baseline for placebo. It also led to a mean body weight reduction of 18 ...

with an average A1C reduction of 1.3% to 1.6% from a baseline of 8%. LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor agonist that can be administered at ...

Orforglipron significantly reduced HbA1c levels by 1.3% (3mg), 1.6% (12mg), and 1.5% (36mg) compared with 0.1% in the placebo arm. Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP ... A1C, a blood level used to diagnose diabetes, by an average ...

A daily GLP-1 pill can help people with type 2 diabetes regulate ... Those who stayed in the trial for the full 40 weeks and took the lowest dose had a 1.3% reduction in A1C from the participants’ ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped ... Participants saw an average reduction of 1.3% to 1.6% from a baseline of 8%.